RLYB
Rallybio CorporationHealthcare·Biotechnology
$14.46
$77M market cap
Revenue
$0.4M
Free Cash Flow
$-12.7M
Rev Growth
+0.0%
FCF Margin
-2916.4%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-tar
2-Year Price History
$15.88+18.9%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.2 | -4.7 | -4.7 | -8.3 | -8.0 | -8.0 | -0.0 | 46.8 | 0.2 | 5.7 | -171.8% | -- | -- |
| Act | 2025-Q4 | 0.2 | -6.4 | -6.4 | -5.9 | -4.7 | -4.7 | -0.0 | 54.7 | 0.2 | 5.3 | -134.9% | -- | -- |
Valuation & Metrics
Market Stats
Price$14.46
Market Cap$77M
Enterprise Value$30M
P/S Ratio176.5x
P/FCF--
EV/FCF--
FCF Margin (TTM)-2916.4%
FCF Yield-16.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.4M
Net Income$-14.1M
Free Cash Flow$-12.7M
Revenue Growth (YoY)+0.0%
EBITDA Margin-2566.6%
Net Margin-3255.8%
FCF Margin-2916.4%
CapEx % of Revenue0.0%
SBC % of Revenue178.3%
ROIC-153.4%
WC Change % Rev187.6%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.6M
Days to Cover28.9
Change (vs Prior)+11.9%
Need at least 2 settlement dates for chart
Employees
Headcount15
Revenue / Employee$28,933
Gross Profit / Employee$28,733
Cash Runway
44.4months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
48.0%(+48.0% YoY)
30 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
2.1%(+2.1% YoY)
6 filers
Vanguard, iShares, SPDR
Market makers
0.2%(+0.2% YoY)
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FMR LLC | $7.1M | $8.97 | +$7.1M | +$7.1M | -0.0% | $1.89T |
| VIKING GLOBAL INVESTORS LP | $4.7M | $8.97 | +$4.7M | +$4.7M | +1.1% | $35.75B |
| Cormorant Asset Management, LLC | $3.6M | $8.97 | +$3.6M | +$3.6M | -2.4% | $1.95B |
| TPG GP A, LLC | $3.4M | $8.97 | +$3.4M | +$3.4M | -2.4% | $3.32B |
| BALYASNY ASSET MANAGEMENT LLC | $3.4M | $8.97 | +$3.4M | +$3.4M | -0.4% | $48.01B |
| Laurion Capital Management LP | $2.7M | $8.97 | +$2.7M | +$2.7M | +2.9% | $1.01B |
| Nantahala Capital Management, LLC | $2.7M | $8.97 | +$2.7M | +$2.7M | -2.4% | $1.60B |
| Pivotal bioVenture Partners Investment Advisor LLC | $2.7M | $8.97 | +$2.7M | +$2.7M | +1.7% | $280M |
| 5AM Venture Management, LLC | $2.6M | $8.97 | +$2.6M | +$2.6M | +0.9% | $360M |
| Almitas Capital LLC | $1.7M | $8.97 | +$1.7M | +$1.7M | +2.7% | $442M |
| RENAISSANCE TECHNOLOGIES LLC | $1.4M | $8.97 | +$1.4M | +$1.4M | +1.2% | $63.91B |
| JOHNSON & JOHNSON | $1.4M | $8.97 | +$1.4M | +$1.4M | -7.0% | $652M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.0M | $8.97 | +$1.0M | +$1.0M | — | $4.04T |
| AJU IB Investment Co., Ltd. | $846K | $8.97 | +$846K | +$846K | -1.1% | $30.5M |
| Mariner, LLC | $454K | $8.97 | +$454K | +$454K | -0.1% | $85.47B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $318K | $8.97 | +$318K | +$318K | +2.3% | $1.61T |
| DELTEC ASSET MANAGEMENT LLC | $303K | $8.97 | +$303K | +$303K | +0.5% | $545M |
| Rangeley Capital, LLC | $270K | $8.97 | +$270K | +$270K | -1.3% | $91.1M |
| GTS SECURITIES LLCMM | $197K | $8.97 | +$197K | +$197K | +0.5% | $2.83B |
| ADAR1 Capital Management, LLC | $184K | $8.97 | +$184K | +$184K | +8.3% | $1.64B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)NEUTRAL
Holders
-0.19%
avg per quarter
Holders (ex-self)
-0.20%
excl. this stock
Buyers (this Q)
-0.19%
38 buyers · $0.04B in
Sellers (this Q)
+0.00%
0 sellers · $0.00B out
alpha coverage: 97% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-6.5%
how holders react when this stock falls
On quiet Qs
-6.0%
−10% to +10% baseline
On rallies (+10%+)
-11.1%
how they react when this stock rises
Holders' portfolio flow this Q
+0.1%
inflows — adds are organic
Sellers' portfolio flow this Q
+0.0%
Sellers' overall flow ~ flat.
Biggest decreases this quarter
New buyers this quarter
FMR LLC+$0.01Bα-0.0VIKING GLOBAL INVESTORS LP+$0.00Bα+1.1Cormorant Asset Management, LLC+$0.00Bα-2.4TPG GP A, LLC+$0.00Bα-2.4BALYASNY ASSET MANAGEMENT LLC+$0.00Bα-0.4Laurion Capital Management LP+$0.00Bα+2.9Nantahala Capital Management, LLC+$0.00Bα-2.4Pivotal bioVenture Partners Investment Advisor LLC+$0.00Bα+1.75AM Venture Management, LLC+$0.00Bα+0.9Almitas Capital LLC+$0.00Bα+2.7
Top-5 holders · 53.0%
FMR LLC--
VIKING GLOBAL INVESTORS LP--
Cormorant Asset Management, LLC--
TPG GP A, LLC--
BALYASNY ASSET MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Not enough holder history to plot.
Analyst Coverage
Analyst Coverage
Analyst Ratings
4
4
Buy: 4Hold: 4Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$4K
1 txn · 1 insider · 789 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$4.23M
8 txns · 1 insider · 302,473 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-19 | BUY | ADAR1 Capital Management, LLC | 10 percent owner | 10,200 | $13.98 | $143K | $12.95M |
| 2026-05-18 | BUY | ADAR1 Capital Management, LLC | 10 percent owner | 6,009 | $13.98 | $84K | $12.80M |
| 2026-05-15 | BUY | ADAR1 Capital Management, LLC | 10 percent owner | 300 | $13.90 | $4K | $12.65M |
| 2026-05-13 | BUY | ADAR1 Capital Management, LLC | 10 percent owner | 79,259 | $13.99 | $1.11M | $12.73M |
| 2026-05-12 | BUY | ADAR1 Capital Management, LLC | 10 percent owner | 800 | $13.83 | $11K | $11.49M |
| 2026-05-11 | BUY | ADAR1 Capital Management, LLC | 10 percent owner | 50,000 | $14.00 | $700K | $11.62M |
| 2026-05-05 | BUY | ADAR1 Capital Management, LLC | 10 percent owner | 35,101 | $14.00 | $491K | $10.91M |
| 2026-05-04 | BUY | ADAR1 Capital Management, LLC | 10 percent owner | 120,804 | $13.97 | $1.69M | $10.40M |
| 2026-02-23 | SELL | Lieber Jonathan I | officer: Chief Financial Officer | 789 | $5.06 | $4K | $21K |
Order Flow (FINRA, ~3w lag)
7.9%retail-8.8pp
29.0%dark+6.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Rallybio Corporation: The 3.65% Remnant - A Reverse Split and Merger Liquidation Thesis
Overall Risk
9/10
Fraud
2/10
Dilution
10/10
Insolvency
8/10
Earnings Overstated
6/10
Hidden Liabilities
4/10
Legal
5/10
Audit Warnings
7/10
Hidden Upside
2/10
Contextually Acceptable
2/10